Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents
This study has been completed.
Study NCT00697775   Information provided by GlaxoSmithKline

First Received on June 12, 2008.   Last Updated on June 13, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis B
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
HBV-MPL vaccine Formulation A
HBV-MPL vaccine Formulation B
Engerix™-B
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services